Skip to main content

Table 4 Actionable Alterations identified in our cohort

From: Genomic features of Chinese small cell lung cancer

Level of evidence based on OncoKB (12/20/2019) Altered genes Mutational type No of patients (%) Related drugs
    25 33.33  
1 NTRK2 Fusions 1 1.33 Entrectinib, Larotrectinib
3 ALK Fusions 1 1.33 Crizotinib
3 BRAF V600E 1 1.33 Dabrafenib, Dabrafenib + Trametinib, Vemurafenib + Cobimetinib, Encorafenib + Binimetinib, Encorafenib + Cetuximab, Encorafenib + Panitumumab, Trametinib, Vemurafenib
3 BRCA2 Oncogenic Mutations 1 1.33 Niraparib, Olaparib, Rucaparib, Rucaparib
3 CDK12 Oncogenic Mutations 1 1.33 Olaparib
3 EGFR Exon 19 deletion, T790M 5 6.67 Afatinib, Dacomitinib, Erlotinib, Gefitinib, Osimertinib
3 ERBB2 Amplification 1 1.33 Ado-Trastuzumab Emtansine, Capecitabine + Trastuzumab + Tucatinib, Lapatinib + Capecitabine, Lapatinib + Letrozole, Margetuximab + Chemotherapy, Neratinib + Capecitabine, Neratinib, Trastuzumab + Pertuzumab + Chemotherapy, Trastuzumab Deruxtecan, Trastuzumab, Trastuzumab + Chemotherapy, Lapatinib + Trastuzumab, Trastuzumab + Pertuzumab, Carboplatin-Taxol Regimen + Trastuzumab
3 PIK3CA Oncogenic Mutations 6 8.00 Fulvestrant + Alpelisib
3 TSC1 Oncogenic Mutations 1 1.33 Everolimus
4 AKT1 E17K 1 1.33 AZD5363
4 FGFR1 Amplification 3 4.00 Debio1347, BGJ398, Erdafitinib
4 HRAS Oncogenic Mutations 3 4.00 Tipifarnib
4 PTEN Oncogenic Mutations 5 6.67 AZD8186, GSK2636771
4 SF3B1 Oncogenic Mutations 2 2.67% H3B-8800
4 U2AF1 Oncogenic Mutations 1 1.33% H3B-8800
Other potentially actionable gene
3 BRCA1 germline 2 4.44% Niraparib, Olaparib(PARPi)
3 BRCA2 germline 1 2.22% Niraparib,Olaparib(PARPi)
3 ATM germline 1 2.22% Olaparib (PARPi)